IVERIC bio, Inc. Common Stock
ISEE
ISEE was delisted on the 10th of July, 2023.
129 hedge funds and large institutions have $1.4B invested in IVERIC bio, Inc. Common Stock in 2015 Q1 according to their latest regulatory filings, with 23 funds opening new positions, 52 increasing their positions, 40 reducing their positions, and 10 closing their positions.
130% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 10
30% more repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 40
11% more funds holding
Funds holding: 116 → 129 (+13)
3% more capital invested
Capital invested by funds: $1.36B → $1.4B (+$46.7M)
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
20% less call options, than puts
Call options by funds: $5.69M | Put options by funds: $7.13M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$41.9M |
| 2 |
Renaissance Technologies
New York
|
+$19.4M |
| 3 |
Morgan Stanley
New York
|
+$10.4M |
| 4 |
Franklin Resources
San Mateo,
California
|
+$7.93M |
| 5 |
AP
AHL Partners
London,
United Kingdom
|
+$5.87M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$51.5M |
| 2 |
SHI
SV Health Investors
Boston,
Massachusetts
|
-$29.5M |
| 3 |
PA
Perceptive Advisors
New York
|
-$19.3M |
| 4 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$13.9M |
| 5 |
Goldman Sachs
New York
|
-$3.54M |
ISEE Hedge Fund Activity: Q1 2015 in Review
129 of the 3,752 institutional investors tracked by Wall St. Rank reported a position in IVERIC bio, Inc. Common Stock (ISEE) for Q1 2015, worth a combined $1.4B — up 3.4% from $1.36B a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new ISEE positions and 10 closed out — a net gain of 13 holders — while 52 added to existing stakes and 40 trimmed.
The largest buyer was OrbiMed, adding an estimated $41.9M. The largest seller was Novo Holdings A/S, cutting an estimated $51.5M.
- 129 institutional investors held IVERIC bio, Inc. Common Stock (ISEE) as of Q1 2015, up from 116 in Q4 2014.
- Funds reported $1.4B of IVERIC bio, Inc. Common Stock stock for Q1 2015, up 3.4% quarter-over-quarter.
- 23 funds opened new IVERIC bio, Inc. Common Stock positions in Q1 2015 and 10 closed out, a net change of +13 holders.
- The largest IVERIC bio, Inc. Common Stock buyer in Q1 2015 was OrbiMed, an estimated $41.9M added.
- The largest IVERIC bio, Inc. Common Stock seller in Q1 2015 was Novo Holdings A/S, an estimated $51.5M sold.
Based on aggregated 13F filings for Q1 2015.